debio1452

AMPCP is an Ecto-5'-nucleotidase (CD73) inhibitor.

Debio-1452-NH3 is a novel and potent FabI antibody—enoyl-acyl carrier protein reductase inhibitor that demonstrates excellent efficacy in reducing bacterial load in mice. It effectively treats lethal infections caused by clinically isolated strains of Pseudomonas aeruginosa (Acinetobacter baumannii), Klebsiella pneumoniae, and Escherichia coli (E. coli).

Afabicin is the prodrug of Debio1452. Debio1452 is an inhibitor FabI, an enzyme critical to fatty acid biosynthesis in staphylococci.

AFN-1252 (Debio 1452)(Debio 1452) is an effective inhibitor of enoyl-acyl carrier protein reductase (FabI). It (≤0.12 μg ml) inhibits all Clinicalal isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Afabicin (Debio 1450) is a precursor drug to Debio1452 that is resistant to Staphylococcus staphylococci and has no significant effect on other Gram-positive and negative bacteria. Debio1452 is a FabI inhibitor that inhibits lipid synthesis in staphylococci.